Barcelona-based biotechnology company developing next-generation targeted therapeutics at the preclinical stage. Created with the backing of Invivo Partners, the company is currently operating in stealth and has not publicly disclosed its molecular targets, technology platform, disease indications or development candidates. Nicole Clarke leads the company as chief executive, and Invivo partner Laura Rodríguez Gallego chairs its board.
